Developer docs
API playgroundTry for free, no card

Search company profiles

Innoviva

Full company profile

uuid0003vmk

Namestring
Innoviva
Legal namestring
Innoviva, Inc.
Websiteurl
inva.com
Company typeenum
Public
Founded yearint
1996
Descriptiontext

Innoviva is a diversified biopharmaceutical company operating three distinct pillars: a durable respiratory royalty portfolio from long-standing GSK-partnered products (Breo Ellipta, Anoro Ellipta, Trelegy), a commercial-stage critical care and infectious disease platform branded Innoviva Specialty Therapeutics (IST), and a strategic healthcare investment portfolio. The company was incorporated in 1996 as Advanced Medicine, later renamed Theravance, and rebranded to Innoviva in January 2016, having originally been established to maximize royalty streams from respiratory products co-developed with GSK. Innoviva is publicly traded on NASDAQ under ticker INVA, headquartered in Burlingame, California, and led by CEO Pavel Raifeld (appointed May 2020) with CFO Steve Basso.

The IST commercial platform markets five FDA-approved products: GIAPREZA (angiotensin II for septic shock), XERAVA (eravacycline for intra-abdominal infections), XACDURO (sulbactam-durlobactam for carbapenem-resistant Acinetobacter pneumonia), ZEVTERA (dalbavancin launched mid-2025 for skin infections), and NUZOLVENCE (zoliflodacin, approved December 2025 as the first new gonorrhea treatment in nearly two decades). FY2025 net product sales reached $172.1M, a 77% year-over-year increase, with U.S. net product sales of $119.2M growing 47% year-over-year. The company generates approximately $250M in gross annual royalty revenue from GSK respiratory products, with expected cumulative royalties exceeding $1.2B through 2030, and reported total FY2025 revenue of $411.3M (15% YoY growth) with $271.2M in net income.

Innoviva's business model combines licensing royalties, direct specialty pharmaceutical sales through its own U.S. commercial organization, international distribution partnerships (Dr. Reddy's for XACDURO in select territories), and strategic capital deployment through minority investments and credit facilities (Armata Pharmaceuticals, Beacon Biosignals, Syndeio Biosciences). The company acquired the LYNX long-acting oral drug delivery platform from Lyndra Therapeutics in 2025 for $10.2M and launched wholly owned subsidiary Nortiva Bio in 2026 to develop once-monthly oral therapies, including a Gates Foundation-funded contraceptive program. With $550.9M in cash and a $614M strategic investment portfolio at the start of 2026, Innoviva pursues a hybrid royalty-asset-management model that funds acquisitions, investments, and share repurchases ($125M program initiated in Q4 2025).

Short descriptiontext

Innoviva is a diversified biopharmaceutical company operating a GSK respiratory royalty portfolio, a commercial critical care and infectious disease platform (Innoviva Specialty Therapeutics) with five FDA-approved antibiotics, and strategic healthcare investments including the LYNX drug delivery platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBurlingame, United States
HQ citystring
Burlingame
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty biopharmaceuticals, infectious disease therapeutics, pharmaceutical royalty management, critical care antibiotics, long-acting drug delivery
Industry3 codes
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Specialty Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Respiratory Royalties from GSK
TypeLicensing Royalties
Description

Royalty streams from respiratory assets partnered with GSK including Relvar Breo Ellipta and Anoro Ellipta, generating approximately $250 million in gross royalty revenue annually. These royalties from COPD and asthma inhaled therapies are expected to exceed $1.2 billion through 2030.

finance.yahoo.com
2Product Sales (Innoviva Specialty Therapeutics)
TypeSubscription Recurring
Description

Net product sales from marketed critical care and infectious disease products including GIAPREZA ($72M in 2025), XACDURO ($33M in 2025), ZEVTERA (launched mid-2025), and NUZOLVENCE (FDA-approved December 2025). IST segment achieved 77% increase in net product sales to $172.1M for full year 2025, with 47% year-over-year U.S. net product sales growth to $119.2M.

pharmiweb.com
3Strategic Healthcare Investments
TypeLicensing Royalties
Description

Portfolio of strategic healthcare investments currently valued at over $600 million, providing optionality, downside protection, and long-term value creation. Includes investments in Armata Pharmaceuticals, Beacon Biosignals, and other healthcare assets.

finance.yahoo.com
4License Revenue
TypeLicensing Royalties
Description

Revenue from licensing and distribution agreements including the Dr. Reddy's agreement for XACDURO covering South and Central America, Caribbean, Russia, and CIS regions, which includes upfront payments, regulatory and commercial milestones, and sales royalties.

finance.yahoo.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1GIAPREZA
Description

FDA-approved treatment for infectious diseases/critical care

inva.com
+6 more records
Core offering1 text field

Innoviva is a diversified biopharmaceutical company that develops, acquires, and commercializes critical care and infectious disease therapies through its Innoviva Specialty Therapeutics platform, generates durable cashflows from royalty streams on GSK-partnered respiratory products (Breo Ellipta, Anoro Ellipta), and maintains a strategic healthcare investment portfolio. Its commercial portfolio includes FDA-approved antibiotics GIAPREZA, XERAVA, XACDURO, ZEVTERA, and NUZOLVENCE.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 47% year-over-year growth in Innoviva Specialty Therapeutics U.S. net product sales to $119.2M
+4 more records
Product overview1 text field

Innoviva is a diversified biopharmaceutical company operating three divisions: (1) a royalty portfolio generating durable cashflows from GSK-partnered respiratory products including Breo Ellipta and Anoro Ellipta; (2) Innoviva Specialty Therapeutics (IST), a critical care and infectious disease platform commercializing five FDA-approved products: GIAPREZA, XERAVA, XACDURO, ZEVTERA, and NUZOLVENCE; and (3) strategic healthcare investments including the LYNX drug delivery platform operated through subsidiary Nortiva Bio, and holdings in companies like Armata Pharmaceuticals, Beacon Biosignals, and Syndeio Biosciences.

Product and service8 records
1GIAPREZA
CategoryCritical Care Therapeutics
Description

FDA-approved angiotensin II injection used to treat septic or distributive shock, marketed to hospitals and critical care prescribers.

2XERAVA
CategoryInfectious Disease Therapeutics
Description

FDA-approved eravacycline antibiotic for the treatment of complicated intra-abdominal infections in adults.

3XACDURO
CategoryInfectious Disease Therapeutics
Description

FDA-approved sulbactam-durlobactam antibiotic for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex.

4ZEVTERA
CategoryInfectious Disease Therapeutics
Description

FDA-approved dalbavancin antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults, launched in the U.S. in mid-2025.

5NUZOLVENCE (zoliflodacin)
CategoryInfectious Disease Therapeutics
Description

First-in-class single-dose oral antibiotic approved by the FDA in December 2025 for the treatment of uncomplicated urogenital gonorrhea in adults.

6Breo Ellipta (Royalty Asset)
CategoryRoyalty Asset
Description

GSK-partnered inhaled respiratory therapy (fluticasone furoate and vilanterol) for the treatment of asthma and COPD, generating royalty revenue for Innoviva.

7Anoro Ellipta (Royalty Asset)
CategoryRoyalty Asset
Description

GSK-partnered inhaled respiratory therapy (umeclidinium and vilanterol) for the treatment of COPD, generating royalty revenue for Innoviva.

8LYNX Drug Delivery Platform
CategoryDrug Delivery Technology
Description

Proprietary drug delivery platform that can transform daily oral pills into long-acting oral therapies with single doses lasting up to a month; developed through subsidiary Nortiva Bio.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-06-16
Description

Innoviva Specialty Therapeutics entered an exclusive licensing and distribution agreement with Dr. Reddy's Laboratories to commercialize XACDURO, an FDA-approved antibiotic for hospital-acquired and ventilator-associated bacterial pneumonia, across South and Central America, the Caribbean, Russia, and the CIS region. Dr. Reddy's will handle development, regulatory approval, and commercialization in those territories while Innoviva retains rights in all other regions and will receive upfront payment, milestone payments, and tiered royalties. The partnership addresses carbapenem-resistant Acinetobacter infection rates exceeding 70% in target regions, classified by WHO as a critical threat pathogen.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-01-01
Description

Innoviva acquired the LYNX drug delivery platform from Lyndra Therapeutics in 2025 for $10.2 million plus up to $20 million in milestones and royalties. The platform enables transformation of daily pills into long-acting oral therapies with potential monthly dosing intervals.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Long-term strategic partnership with GSK for respiratory products including Relvar Breo Ellipta and Anoro Ellipta, generating approximately $250 million in gross royalty revenue annually with expected $1.2 billion+ through 2030. Innoviva previously repurchased GSK's equity stake in 2021.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat5 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries8 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment20 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Innoviva

Specialty Pharmaceuticalsinva.com

Innoviva is a diversified biopharmaceutical company operating a GSK respiratory royalty portfolio, a commercial critical care and infectious disease platform (Innoviva Specialty Therapeutics) with five FDA-approved antibiotics, and strategic healthcare investments including the LYNX drug delivery platform.

What Innoviva does

Innoviva is a diversified biopharmaceutical company operating three distinct pillars: a durable respiratory royalty portfolio from long-standing GSK-partnered products (Breo Ellipta, Anoro Ellipta, Trelegy), a commercial-stage critical care and infectious disease platform branded Innoviva Specialty Therapeutics (IST), and a strategic healthcare investment portfolio. The company was incorporated in 1996 as Advanced Medicine, later renamed Theravance, and rebranded to Innoviva in January 2016, having originally been established to maximize royalty streams from respiratory products co-developed with GSK. Innoviva is publicly traded on NASDAQ under ticker INVA, headquartered in Burlingame, California, and led by CEO Pavel Raifeld (appointed May 2020) with CFO Steve Basso.

The IST commercial platform markets five FDA-approved products: GIAPREZA (angiotensin II for septic shock), XERAVA (eravacycline for intra-abdominal infections), XACDURO (sulbactam-durlobactam for carbapenem-resistant Acinetobacter pneumonia), ZEVTERA (dalbavancin launched mid-2025 for skin infections), and NUZOLVENCE (zoliflodacin, approved December 2025 as the first new gonorrhea treatment in nearly two decades). FY2025 net product sales reached $172.1M, a 77% year-over-year increase, with U.S. net product sales of $119.2M growing 47% year-over-year. The company generates approximately $250M in gross annual royalty revenue from GSK respiratory products, with expected cumulative royalties exceeding $1.2B through 2030, and reported total FY2025 revenue of $411.3M (15% YoY growth) with $271.2M in net income.

Innoviva's business model combines licensing royalties, direct specialty pharmaceutical sales through its own U.S. commercial organization, international distribution partnerships (Dr. Reddy's for XACDURO in select territories), and strategic capital deployment through minority investments and credit facilities (Armata Pharmaceuticals, Beacon Biosignals, Syndeio Biosciences). The company acquired the LYNX long-acting oral drug delivery platform from Lyndra Therapeutics in 2025 for $10.2M and launched wholly owned subsidiary Nortiva Bio in 2026 to develop once-monthly oral therapies, including a Gates Foundation-funded contraceptive program. With $550.9M in cash and a $614M strategic investment portfolio at the start of 2026, Innoviva pursues a hybrid royalty-asset-management model that funds acquisitions, investments, and share repurchases ($125M program initiated in Q4 2025).

Innoviva firmographics

Firmographics
Name
Innoviva
Legal name
Innoviva, Inc.
Website
https://inva.com
Company type
Public
Founded year
1996
Operating status
Operating
Headcount range
11–50 employees
Short description
Innoviva is a diversified biopharmaceutical company operating a GSK respiratory royalty portfolio, a commercial critical care and infectious disease platform (Innoviva Specialty Therapeutics) with five FDA-approved antibiotics, and strategic healthcare investments including the LYNX drug delivery platform.
Ownership category
akta.pro rank

Innoviva industry classification

Industry
Product category
Specialty Pharmaceuticals
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAO
Specialty Injectable & Infusion Therapies (Cross-therapeutic)
SECONDARYHLAIAAAJ
Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty biopharmaceuticals
  • Infectious disease therapeutics
  • Pharmaceutical royalty management
  • Critical care antibiotics
  • Long-acting drug delivery

Where Innoviva is headquartered

Location

Headquarters

HQ city
Burlingame
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Innoviva business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Operations, Supply Chain

Revenue model

  1. Respiratory Royalties from GSK: Royalty streams from respiratory assets partnered with GSK including Relvar Breo Ellipta and Anoro Ellipta, generating approximately $250 million in gross royalty revenue annually. These royalties from COPD and asthma inhaled therapies are expected to exceed $1.2 billion through 2030.
  2. Product Sales (Innoviva Specialty Therapeutics): Net product sales from marketed critical care and infectious disease products including GIAPREZA ($72M in 2025), XACDURO ($33M in 2025), ZEVTERA (launched mid-2025), and NUZOLVENCE (FDA-approved December 2025). IST segment achieved 77% increase in net product sales to $172.1M for full year 2025, with 47% year-over-year U.S. net product sales growth to $119.2M.
  3. Strategic Healthcare Investments: Portfolio of strategic healthcare investments currently valued at over $600 million, providing optionality, downside protection, and long-term value creation. Includes investments in Armata Pharmaceuticals, Beacon Biosignals, and other healthcare assets.
  4. License Revenue: Revenue from licensing and distribution agreements including the Dr. Reddy's agreement for XACDURO covering South and Central America, Caribbean, Russia, and CIS regions, which includes upfront payments, regulatory and commercial milestones, and sales royalties.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Innoviva product offering

Product offering

Core offering

Innoviva is a diversified biopharmaceutical company that develops, acquires, and commercializes critical care and infectious disease therapies through its Innoviva Specialty Therapeutics platform, generates durable cashflows from royalty streams on GSK-partnered respiratory products (Breo Ellipta, Anoro Ellipta), and maintains a strategic healthcare investment portfolio. Its commercial portfolio includes FDA-approved antibiotics GIAPREZA, XERAVA, XACDURO, ZEVTERA, and NUZOLVENCE.

Product overview

Innoviva is a diversified biopharmaceutical company operating three divisions: (1) a royalty portfolio generating durable cashflows from GSK-partnered respiratory products including Breo Ellipta and Anoro Ellipta; (2) Innoviva Specialty Therapeutics (IST), a critical care and infectious disease platform commercializing five FDA-approved products: GIAPREZA, XERAVA, XACDURO, ZEVTERA, and NUZOLVENCE; and (3) strategic healthcare investments including the LYNX drug delivery platform operated through subsidiary Nortiva Bio, and holdings in companies like Armata Pharmaceuticals, Beacon Biosignals, and Syndeio Biosciences.

Differentiator

Problem solved

Functional benefit

Brands

  • GIAPREZA: FDA-approved treatment for infectious diseases/critical care
  • XERAVA
  • XACDURO
  • ZEVTERA
  • NUZOLVENCE
  • LYNX
  • Nortiva Bio

Products and services

  • GIAPREZA FDA-approved angiotensin II injection used to treat septic or distributive shock, marketed to hospitals and critical care prescribers.
  • XERAVA FDA-approved eravacycline antibiotic for the treatment of complicated intra-abdominal infections in adults.
  • XACDURO FDA-approved sulbactam-durlobactam antibiotic for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex.
  • ZEVTERA FDA-approved dalbavancin antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults, launched in the U.S. in mid-2025.
  • NUZOLVENCE (zoliflodacin) First-in-class single-dose oral antibiotic approved by the FDA in December 2025 for the treatment of uncomplicated urogenital gonorrhea in adults.
  • Breo Ellipta (Royalty Asset) GSK-partnered inhaled respiratory therapy (fluticasone furoate and vilanterol) for the treatment of asthma and COPD, generating royalty revenue for Innoviva.
  • Anoro Ellipta (Royalty Asset) GSK-partnered inhaled respiratory therapy (umeclidinium and vilanterol) for the treatment of COPD, generating royalty revenue for Innoviva.
  • LYNX Drug Delivery Platform Proprietary drug delivery platform that can transform daily oral pills into long-acting oral therapies with single doses lasting up to a month; developed through subsidiary Nortiva Bio.

Quantifiable outcome

  • 47% year-over-year growth in Innoviva Specialty Therapeutics U.S. net product sales to $119.2M
  • +4 more outcomes

Companies that use Innoviva

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Innoviva technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Innoviva partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Dr. Reddy's LaboratoriescoreChannel Partner/ Reseller/ Distributor · 16 June 2026Innoviva Specialty Therapeutics entered an exclusive licensing and distribution agreement with Dr. Reddy's Laboratories to commercialize XACDURO, an FDA-approved antibiotic for hospital-acquired and ventilator-associated bacterial pneumonia, across South and Central America, the Caribbean, Russia, and the CIS region. Dr. Reddy's will handle development, regulatory approval, and commercialization in those territories while Innoviva retains rights in all other regions and will receive upfront payment, milestone payments, and tiered royalties. The partnership addresses carbapenem-resistant Acinetobacter infection rates exceeding 70% in target regions, classified by WHO as a critical threat pathogen.
  • Lyndra TherapeuticscoreTechnology or Integration · 1 January 2025Innoviva acquired the LYNX drug delivery platform from Lyndra Therapeutics in 2025 for $10.2 million plus up to $20 million in milestones and royalties. The platform enables transformation of daily pills into long-acting oral therapies with potential monthly dosing intervals.
  • GSKcoreStrategic or Co-development Partner · 1 January 2022Long-term strategic partnership with GSK for respiratory products including Relvar Breo Ellipta and Anoro Ellipta, generating approximately $250 million in gross royalty revenue annually with expected $1.2 billion+ through 2030. Innoviva previously repurchased GSK's equity stake in 2021.

Scale indicators16 records

Recent moves8 records

Expansion highlights5 records

Innoviva competitors and assessment

Company assessment

Market position

Competitive moat5 records

Key highlights7 records

Customer concentration

Innoviva social profiles

Digital presence

Innoviva financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Innoviva leadership team

Management profile

Number of profiles

Profiles7 records

Innoviva subsidiaries and ownership

Company hierarchy

Subsidiaries8 records

Innoviva funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Innoviva M&A and investment

M&A and investment

M&A2 records

Investments20 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Innoviva

What does Innoviva do?

Innoviva is a diversified biopharmaceutical company that develops, acquires, and commercializes critical care and infectious disease therapies through its Innoviva Specialty Therapeutics platform, generates durable cashflows from royalty streams on GSK-partnered respiratory products (Breo Ellipta, Anoro Ellipta), and maintains a strategic healthcare investment portfolio. Its commercial portfolio includes FDA-approved antibiotics GIAPREZA, XERAVA, XACDURO, ZEVTERA, and NUZOLVENCE.

Is Innoviva a public or private company?

Innoviva is a public company. It is classified as public and is currently operating.

When was Innoviva founded?

Innoviva was founded in 1996. It employs 11 to 50 people.

Where is Innoviva based?

Innoviva is headquartered in Burlingame, United States, in the North America region.

How does Innoviva make money?

Four revenue lines are on record. Respiratory Royalties from GSK is the primary driver. The others are product Sales (Innoviva Specialty Therapeutics), strategic Healthcare Investments and license Revenue.

Does Innoviva have an API?

No public API is recorded for Innoviva.

What industry is Innoviva in?

Innoviva's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAO, Specialty Injectable & Infusion Therapies (Cross-therapeutic). Its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaInnoviva gains new Overweight at Piper Sandler on diversified strategyPiper Sandler initiated coverage of Innoviva with an Overweight rating, citing its diversified biopharma exposure. The firm set a $29 price target, noting Innoviva's royalty portfolio and hospital-focused brand assets. The company trades at an EV/2027E EBITDA multiple of about 6x.TradingViewInnoviva gains new Overweight at Piper Sandler on diversified strategyPiper Sandler initiated coverage of Innoviva with an Overweight rating, citing its diversified biopharma exposure. The firm set a $29 price target, noting Innoviva's royalty portfolio and hospital-focused assets. The company trades at an EV/2027E EBITDA multiple of about 6x.YahooIs Quarterly Loss Altering The Investment Case For Innoviva Stock (INVA)?Innoviva reported Q3 2026 revenue of $106.12 million and a net loss of $73.89 million, while a nine-month update showed higher revenue but lower net income. The company completed a $92.34 million buyback of 5.82% of shares, and analysts project $551.1 million revenue and $214.6 million earnings by 2029.Simply Wall StQuarterly Loss Could Be A Game Changer For Innoviva (INVA)Innoviva reported Q3 2026 revenue of $106.12 million and a net loss of $73.89 million, a sharp swing from prior-year profit. The company completed a $92.34 million buyback of 4.28 million shares, while analysts expect revenue to reach $551.1 million by 2029.American Banking and Market NewsCenterBook Partners LP Purchases 40,904 Shares of Innoviva, Inc. $INVACenterBook Partners LP acquired 40,904 shares of Innoviva, valued at about $868,000, in the third quarter. The purchase represents a new stake, and institutional investors own 99.12% of the company's stock. Analysts have a consensus rating of Moderate Buy with a price target of $39.00.American Banking and Market NewsInnoviva (NASDAQ:INVA) Price Target Cut to $34.00 by Analysts at OppenheimerOppenheimer cut Innoviva's price target to $34.00 from $35.00, keeping an outperform rating. Other analysts also adjusted ratings, with a consensus of Moderate Buy and $39.00 target. The stock opened at $19.24, and the company reported a loss of $1.03 per share for the quarter.MarketBeatInnoviva, Inc. $INVA Stock Holdings Reduced by Assenagon Asset Management S.A.Assenagon Asset Management cut its Innoviva stake by 47.9% in Q3, selling 212,639 shares and leaving 231,583 shares. Other funds like Farther Finance and Versant Capital added positions, while analysts issued mixed ratings with a consensus 'Moderate Buy' and $39.25 target.ChartmillInnoviva Inc (NASDAQ:INVA): A Decent Value Stock With an Undervalued Earnings ProfileINNOVIVA INC is flagged by the Decent Value screen with a 7/10 valuation score, 8/10 health, 7/10 profitability, and 7/10 growth. The stock trades at a P/E of 11.52, cheaper than 90.58% of peers, but forward earnings are expected to decline 12.99%.Markets DailySynaptogenix (NASDAQ:TAOX) and Innoviva (NASDAQ:INVA) Critical ContrastInnoviva beats Synaptogenix on 11 of 14 factors, including institutional ownership, beta, and analyst ratings. Innoviva has higher revenue and earnings, with a consensus target price of $39.25 implying 88.88% upside. Synaptogenix trades at a lower P/E but is unprofitable.American Banking and Market NewsContrasting Rafael (NYSE:RFL) and Innoviva (NASDAQ:INVA)Innoviva and Rafael are compared on analyst ratings, valuation, and profitability. Innoviva has a stronger consensus rating, higher revenue and earnings, and a higher upside target, beating Rafael on 12 of 14 factors. Rafael trades at a lower P/E but is unprofitable.